Disagree. This is yet another poor annoucement from RS.
It's disappointing that Sensera continue to explore different "revenue-generating" avenues with complete disregard for profitability which is what actually flows through to the share price and ultimately shareholders.
Ann: Organ-on-Chip A Growing MedTech Opportunity for Sensera, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
